** U.S.-listed shares of the maker ofcannabis-based drugs up 4 pct at $91.99 premarket
** The UK-based company has started the second legof a mid-stage trial testing Epidiolex to treat Dravet syndrome,a rare, treatment-resistant form of childhood epilepsy
** Data from the trial is expected at end of year and GWexpects to submit a marketing application to the FDA in mid-2016
** Epidiolex to also undergo late-stage testing to treat Lennox-Gastaut syndrome; studies expected to start in Q2
** GW shares have been on a roll on hopes for its so-calledcannabinoid medicines since the firm listed on Nasdaq in 2013
** Despite saying on Jan. 8 its drug Sativex failed toalleviate pain in cancer patients, stock had risen about 24 pctsince then through Monday